Serena Williams has announced to the world loud and proud that she's been taking GLP-1 medication in a bid to lose 31 pounds.

While diet and exercise remain the foundation for many, more and more stars are openly admitting to using weight-loss ...

Through innovation, cost discipline, legal action, and competitive pricing, Novo Nordisk has reasserted its leadership in the GLP-1 market. With a robust pipeline and global expansion, NVO is poised ...

A Comeback Fueled by Resilience Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) has been a trailblazer in the GLP-1 drug ...

Mounjaro and other GLP-1 drugs may lower cancer risk in obese patients, according to a new study. Read more here.

A MAJOR high street pharmacy has stopped selling Mounjaro amid a nationwide shortage of the popular fat jab. It comes just days after The Sun revealed the price of the ‘King Kong’ injection would ...

Lilly's obesity pill orforglipron disappointed with lower weight loss, but its broad late-stage pipeline keeps growth hopes ...

Fans rubbed their eyes in disbelief after Meghan Trainor shared a video of herself attempting a wild and risky challenge ...

Serena Williams has left fans concerned after she revealed a dramatic new-look following her major weight loss. The ...

The plant — which was acquired last year by Novo Nordisk and has a history of troubled inspections — was cited for having cat hair, pests, and bacteria, a recent FDA inspection showed.

With the price of weight-loss injection Mounjaro rising by 170 per cent next month, we asked a pharmacist and medical ...

In the wake of weight-loss drugs and the rising importance of health, the iconic cultural brand must double down on its roots ...